Information Provided By: 
Fly News Breaks for May 30, 2019
CALA
May 30, 2019 | 08:27 EDT
Citi analyst Mohit Bansal assumed coverage Calithera Biosciences with a Buy rating and $10 price target. Under a prior analyst, Citi had a Buy rating on the shares with a $7 price target. Positive data mid-year from the small metastatic renal cell carcinoma trial could have read-through to the Cabo trial, Bansal tells investors in a research note.
News For CALA From the Last 2 Days
There are no results for your query CALA
